Master Services Agreement Pharma Template and Key Clauses (2026)

What is a pharma master services agreement, and when do you need one? A pharma master services agreement (MSA) is a framework contract between a pharmaceutical, biotech or medical-device company and a service provider, under which a range of services can be ordered through individual work orders or statements of work without renegotiating the whole contract each time. It is used across the life-sciences supply chain, for example with contract research organisations, contract manufacturers, laboratories, clinical-supply, data and consulting providers. What makes a pharma MSA different from a generic MSA is the layer of regulated-industry terms it carries: quality and good-practice (GxP) standards, pharmacovigilance and safety-data exchange, regulatory audit and inspection rights, and careful handling of intellectual property and confidential data. You need one when you will use a provider repeatedly and the work touches regulated activities or sensitive data. The MSA settles the terms that should stay constant, such as quality, compliance, IP, confidentiality, data protection and liability, while each work order fills in the specific services, timelines and price. A well-structured MSA, with a separate quality agreement and safety-data-exchange agreement where needed, lets a regulated company move quickly on new work while keeping its compliance obligations intact. This article is general guidance, not legal advice. Life-sciences regulation varies by jurisdiction and is complex, so have qualified regulatory and legal professionals review any pharma MSA. ## Pharma master services agreement template Copy the block below and fill the bracketed fields. In practice, quality and safety detail usually sit in separate linked agreements. ```

MASTER SERVICES AGREEMENT (PHARMA / LIFE SCIENCES) This Master Services Agreement ("Agreement") is made on [DATE] BETWEEN: [COMPANY NAME], [address] ("Company") AND [PROVIDER NAME], [address] ("Provider") 1. STRUCTURE This Agreement governs services ordered through Work Orders / Statements of Work ("SOWs"). Each SOW sets the services, deliverables, timeline and price, and is governed by these terms. These terms prevail over conflicting SOW terms unless an SOW expressly overrides a specified clause. 2. SERVICES AND STANDARDS The Provider will perform the services with reasonable skill and care, by suitably qualified personnel, in accordance with each SOW, the applicable good-practice standards (GxP, for example GMP, GLP or GCP as relevant), and all applicable laws and regulatory requirements. 3. QUALITY AGREEMENT Where the services are GxP-regulated, a separate Quality Agreement governs quality responsibilities and controls and is incorporated by reference. If there is a conflict on a quality matter, the Quality Agreement prevails. 4. PHARMACOVIGILANCE / SAFETY DATA Where relevant, a separate Safety Data Exchange Agreement governs adverse-event and safety-information handling and reporting timelines. 5. REGULATORY, AUDIT AND INSPECTION The Provider will support regulatory submissions as agreed, keep required records, and allow the Company and regulators to audit and inspect relevant facilities, records and systems. 6. CONFIDENTIALITY Each party protects the other's confidential information and uses it only to perform this Agreement. 7. DATA PROTECTION AND SECURITY Where personal or health data is processed, the Provider processes it only on the Company's instructions, applies agreed security measures, and signs a data processing agreement where required. 8. INTELLECTUAL PROPERTY Each party keeps its background IP. IP created in performing an SOW belongs to the Company (or as the SOW states), and the Provider assigns or licenses it accordingly. The Provider will not use the Company's IP or data to train models or for any other purpose without written consent. 9. SUPPLY, MATERIALS AND TITLE (where applicable) For manufacturing or supply SOWs, terms on materials, specifications, release, title and risk, and handling of non-conforming product. 10. WARRANTIES AND COMPLIANCE The Provider warrants it and its personnel are not debarred or disqualified by a relevant regulator, and that it will maintain required licences and registrations. 11. LIABILITY AND INDEMNITY Liability is allocated here, with indemnities for IP infringement, breach of confidentiality or data terms, and regulatory or quality breaches, subject to caps and exclusions for indirect loss to the extent the law allows. 12. INSURANCE Each party maintains appropriate insurance, including product-liability and professional cover as relevant, of [amounts]. 13. TERM AND TERMINATION This Agreement runs from [START] for [term] and renews [by agreement]. Either party may terminate for material breach or insolvency. Active SOWs continue or wind down as agreed, with an orderly transfer of data, materials and records. 14. GOVERNING LAW AND DISPUTES This Agreement is governed by the laws of [jurisdiction], with disputes subject to [arbitration seat / courts]. Signed for the Company: __________ Signed for the Provider: __________ Name / title / date Name / title / date LINKED DOCUMENTS - Quality Agreement, Safety Data Exchange Agreement, SOWs

- **Standards and quality agreement (clauses 2 and 3).** Name the good-practice standards that apply (GMP for manufacturing, GLP for labs, GCP for clinical) and put the detailed quality responsibilities in a separate quality agreement, which is standard practice in regulated supply.
- **Pharmacovigilance (clause 4).** If the work can generate safety information, a safety-data-exchange agreement with strict reporting timelines belongs alongside the MSA. Do not try to cover pharmacovigilance in a single MSA line.
- **Intellectual property and data use (clause 8).** Make clear that IP created under an SOW belongs to the company, and that the provider may not use the company's data or IP for anything outside the services, including training AI models, without written consent.
- **Debarment warranty (clause 10).** A warranty that the provider and its personnel are not debarred or disqualified by a regulator is a standard and important protection in life sciences. ## Common mistakes to avoid - No clear order of precedence between the MSA, the quality agreement and the SOWs.
- Trying to cover quality and pharmacovigilance inside the MSA instead of in dedicated linked agreements.
- Leaving IP ownership of SOW deliverables unclear, or silent on whether the provider can reuse company data.
- No debarment or licence-maintenance warranty from the provider.
- Weak termination and transition terms, so data, materials and records are hard to recover when the relationship ends. ## A note on jurisdiction A pharma MSA is a framework services contract overlaid with regulated-industry terms, and both the background contract law and the regulatory layer vary by jurisdiction. In India, the services contract sits under the Indian Contract Act, 1872, GST applies to the services, and the regulatory layer draws on the Drugs and Cosmetics framework, the clinical-trials rules under CDSCO, and good-practice standards. In the UK, EU, Ireland, Singapore, Australia and the US, equivalent regulators (for example national medicines agencies) and good-practice standards apply, data-protection regimes differ, and product-liability and pharmacovigilance rules have local forms. International good-practice guidance (such as ICH and PIC/S) is widely referenced but is applied through national rules. Because a regulated company often operates across borders, treat the quality, safety, data-protection and product-liability requirements as varying by jurisdiction, apply the strictest applicable standard where needed, and confirm the current rules with regulatory counsel. Last verified October 2026. ## Where a contract workspace helps A pharma MSA settles the framework while work orders run against it, and the surrounding work is large: keeping quality, pharmacovigilance, IP and data terms consistent across many providers and SOWs, checking each provider's proposed amendments before signing, and tracking renewals, audit rights, licence expiries and transition obligations across a web of linked agreements. An AI workspace can model the MSA, the quality agreement and the SOWs as linked clauses so the dependencies and per-clause risk show up, let you edit in plain language, and keep renewal, audit and licence dates on one timeline. [Adira](https://adiralaw.com) is one example of a workspace built for linked agreements of this kind. The template and notes are enough to understand a pharma MSA, while the regulatory review itself stays with qualified professionals.